Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals
10 September 2020
Approximately one in five patients with bloodstream infections in US hospitals received discordant empirical antibiotic therapy, receipt of which was closely associated with infection with antibiotic-resistant pathogens. Receiving discordant empirical antibiotic therapy was associated with increased odds of mortality overall, even in patients without sepsis. Early identification of bloodstream pathogens and resistance will probably improve population-level outcomes.
Further reading: The Lancet Infectious Diseases
Author(s): Sameer S Kadri, MD Yi Ling Lai, MPH Sarah Warner, MPH Jeffrey R Strich, MD Ahmed Babiker, MBBS Emily E Ricotta, PhD Cumhur Y Demirkale, PhD John P Dekker, MD Tara N Palmore, MD Chanu Rhee, MD Prof Michael Klompas, MD Prof David C Hooper, MD John H Powers 3rd, MD Arjun Srinivasan, MD Robert L Danner, MD Jennifer Adjemian, PhD
Healthy Patients
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Global Ambassador Network
Welcome at the AMR Insights Ambassador Network!
The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).
